Trump taking anti-malaria drug despite studies that show it has no impact on Covid-19

A pharmacist holds up packets of hydroxychloroquine, April, 2020.
A pharmacist holds up packets of hydroxychloroquine, April, 2020. Yves Herman/Reuters

U.S. President Donald Trump, in a surprise announcement, said on Monday he is taking hydroxychloroquine as a preventive medicine against the coronavirus despite medical warnings about the use of the malaria drug.


"I'm taking hydroxychloroquine," Trump told reporters. "I've been taking it for the last week and a half. A pill every day."

Trump volunteered the disclosure during a question-and-answer session with reporters as he met restaurant executives whose businesses are reeling from the impact of the virus.

The anti-inflammatory has been touted by Trump among others as a potential "game changer", after initial studies in lab settings showed it may be able to prevent the virus replicating.

Studies dismiss Hydroxychloroquine

But several subsequent studies -- including one funded by the US government -- appear to have doused hopes that HCQ can help patients hospitalised with COVID-19.

In the first study released Friday, researchers in France monitored 181 patients hospitalised with pneumonia due to COVID-19 and who needed oxygen.

Eighty-four were treated with HCQ and 97 were not.

They found no meaningful difference between the groups for either transfer to intensive care, death within seven days or developing acute respiratory distress syndrome within 10 days.

"Hydroxychloroquine has received worldwide attention as a potential treatment for COVID-19 because of positive results from small studies," said the authors of the research, published in the BMJ journal.

"However, the results of this study do not support its use in patients admitted to hospital with COVID-19 who require oxygen."

Chinese study

A second study saw researchers in China split 150 COVID-19 patients in to two groups, one of which received HCQ.

After four weeks tests revealed similar rates of sustained infection among both groups, though adverse reactions to treatment were more common in the HCQ group.

Nor did the severity or duration of symptoms differ between each group.

Hydroxychloroquine and a related compound chloroquine have been used for decades to treat malaria, as well as the autoimmune disorders lupus and rheumatoid arthritis.

Last month the European Medicines Agency warned that there was no indication HCQ could treat COVID-19 and said some studies had seen serious and sometimes fatal heart problems in patients.


Daily newsletterReceive essential international news every morning

Keep up to date with international news by downloading the RFI app